Expansion Opportunity Cresilon is rapidly expanding its biomanufacturing capacity in Brooklyn to 55,000 square feet, signaling increasing demand for its hemostatic technologies. This creates potential sales opportunities for contract manufacturing, raw materials supply, logistics, and distribution partnerships to support scale.

Trauma Gel Demand With TRAUMAGEL nationwide launch and presence at high-profile trauma conferences, there is a clear market push for access to advanced hemostatic products in U.S. emergency and battlefield settings, presenting cross-sell opportunities to hospitals, EMS, disaster response programs, and military contractors.

Clinical Validation Selected for poster presentations at ATLS Global Symposium and multiple FDA clearances indicate strong clinical validation and regulatory momentum, enabling targeted outreach to procurement and clinical trial teams seeking validated devices for wound care and hemorrhage control.

Financial Momentum Recent multi-million dollar funding rounds and a high-growth footprint support expanded go-to-market, distribution networks, and product line extensions, suggesting readiness for partnerships with distributors, integration into surgical suites, and international expansion opportunities.

Market Leadership Recognized as a leading innovator in medical devices and with rapid product launches, Cresilon presents a strong value proposition for hospital systems, urgent care networks, and VA/defense programs seeking cutting-edge hemostatic solutions and reliable supply chains.